Good morning.
Wednesday morning, the FDA's Pharmacy Compounding Advisory Committee sits down in Silver Spring to evaluate seven research peptides for the 503A compounding list. BPC-157. TB-500. Semax. Epitalon. Emideltide. KPV. MOTs-C.
The public docket for this meeting closes Wednesday, July 22, at 11:59 p.m. Eastern. You can still comment, and it's worth doing.
Seven peptides in front of the committee
The Pharmacy Compounding Advisory Committee meets July 23 and 24 to evaluate seven bulk drug substances for the 503A compounding list. That list determines which compounds 503A compounding pharmacies can legally use. A favorable vote means a compound has a clearer legal path. An unfavorable one doesn't create an automatic ban, but it builds the regulatory record FDA draws on when it decides where to apply enforcement pressure. And that pressure reaches the research market too.
The seven compounds on the table:
Wednesday, July 23: BPC-157 (ulcerative colitis), KPV (wound healing and inflammatory conditions), TB-500 (wound healing), and MOTs-C (obesity and osteoporosis).
Thursday, July 24: Emideltide, also known as DSIP (opioid withdrawal, insomnia, narcolepsy), Semax (cerebral ischemia, migraine, trigeminal neuralgia), and Epitalon (insomnia).
If you recognize those names, this meeting is about compounds you know.
The comment docket closes Wednesday
The public docket for this meeting closes at 11:59 p.m. Eastern on Wednesday, July 22. Comments received before July 9 went directly to the committee. Comments submitted between now and July 22 will, in FDA's words, "be taken into consideration by FDA." That's still worth doing.
You don't need legal expertise. Patient experience, researcher notes, what a compound has done and why you use it. That's the kind of material that fills a useful docket. Submit at regulations.gov, Docket FDA-2025-N-6895.
The committee's recommendations are non-binding. FDA doesn't have to follow them. But in practice, how these votes go matters.
One more thing from the research
A University of Pennsylvania study published in June followed 111,646 women and found that those taking GLP-1 medications had roughly 30% lower odds of developing breast cancer than women who weren't. In a matched cohort adjusted for age, BMI, race, and diabetes status, the reduction was 30.5%. That's about seven fewer diagnoses per 1,000 women during the study period.
This is observational research, not a randomized trial. It finds an association, not a cause. The researchers called it hypothesis-generating and said a proper trial is needed before anyone draws clinical conclusions. A Phase 3 trial called ORCA is now evaluating semaglutide in high-risk cancer prevention populations, with results years out.
The mechanism being studied involves GLP-1s' effects on adipose tissue and systemic inflammation. Excess body fat raises circulating estrogen levels after menopause, and GLP-1s alter that equation. The sample size is large and the matching was careful. The signal is worth knowing about, with the caveats attached.
Reader discounts
A few standing codes active this week, all from vendors B-rated or better in our database:
Ascension Peptides (code PPL) is 50% off. That's the biggest standing discount in our database.
Double R Labs and Soma Chems are both 15% off with code PPL.
Alpha Peptides is 10% off every order, also with code PPL.
These are permanent reader codes, not flash sales. PPL earns a commission if you use the affiliate links above, at no cost to you.
Tirzepatide and semaglutide are prescription medications. Nothing here is medical advice. Regulatory status is current as of July 18, 2026 and can change.